EDG-7500 Clinical Trials (2026): 6 Studies for Healthy Adult Participants & Healthy Subjects
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
6 EDG-7500 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Healthy Adult Participants & Healthy Subjects) and 285 total planned enrollment. 2 EDG-7500 clinical trials are actively recruiting at 2 U.S. sites across 1 state. Most recent activity: NCT06347159 (Dec 2026).
Where to Participate: All EDG-7500 Trial Sites in the U.S. (2 sites across 1 state)
Every actively recruiting EDG-7500trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | The University of Miami Division of Clinical Pharmacology | Miami33136 | NCT07324616 | Map |
| FL | Orlando Clinical Research Center | Orlando32809 | NCT07324616 | Map |
EDG-7500 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | not yet recruiting | Total |
|---|---|---|---|---|---|
| P1 | 1 | 3 | 1 | 5 | |
| P2 | 1 | 1 |
Recruiting EDG-7500 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07456059 | A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults | P1 | Healthy Adult Participants | 24 | Mar 2026 |
| NCT07324616 | A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment | P1 | Hepatic Impairment (HI) | 32 | Jan 2026 |
EDG-7500 clinical trials by indication
Healthy Adult Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07456059 | — | P1 | not yet recruiting | A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults |
Hepatic Impairment (HI) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07324616 | — | P1 | recruiting | A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment |
Renal Impairments (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07034768 | — | P1 | completed | A Study to Evaluate EDG-7500 in People With Renal Impairment |
Healthy Volunteer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06738836 | — | P1 | completed | A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500 |
Hypertrophic Cardiomyopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06347159 | CIRRUS-HCM | P2 | active not recruiting | A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) |
Healthy Subjects (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06011317 | — | P1 | completed | A Study of EDG-7500 in Healthy Adults |
EDG-7500 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| CIRRUS-HCM | NCT06347159 | P2 | active not recruiting | Hypertrophic Cardiomyopathy | 100 | — |
All EDG-7500 trials (6)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06347159 | CIRRUS-HCM | A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) | P2 | active not recruiting | 100 | Edgewise Therapeutics, Inc. | Apr 2024 |
| NCT07456059 | A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults | P1 | not yet recruiting | 24 | Edgewise Therapeutics, Inc. | Mar 2026 | |
| NCT07324616 | A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment | P1 | recruiting | 32 | Edgewise Therapeutics, Inc. | Jan 2026 | |
| NCT07034768 | A Study to Evaluate EDG-7500 in People With Renal Impairment | P1 | completed | 37 | Edgewise Therapeutics, Inc. | Jul 2025 | |
| NCT06738836 | A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500 | P1 | completed | 8 | Edgewise Therapeutics, Inc. | Dec 2024 | |
| NCT06011317 | A Study of EDG-7500 in Healthy Adults | P1 | completed | 84 | Edgewise Therapeutics, Inc. | Aug 2023 |
EDG-7500 clinical trials: frequently asked questions
- How many EDG-7500 clinical trials are there?
- 6 EDG-7500 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 3 are marked completed.
- Are EDG-7500 clinical trials recruiting in 2026?
- Yes — 1 EDG-7500 trial is actively recruiting in 2026, with 2 U.S. sites across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is EDG-7500 being studied for?
- EDG-7500 is being studied for Healthy Adult Participants, Healthy Subjects, Healthy Volunteer, Hepatic Impairment (HI), Hypertrophic Cardiomyopathy and 1 more. The trials are grouped by indication on this page.
- What phase is EDG-7500 in?
- EDG-7500 clinical trials span 1 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors EDG-7500 clinical trials?
- The lead sponsor across the most EDG-7500 trials is Edgewise Therapeutics, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming EDG-7500as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: